These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33668856)

  • 1. Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.
    Khalsa JK; Shah K
    Cells; 2021 Feb; 10(3):. PubMed ID: 33668856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
    Khalsa JK; Cheng N; Keegan J; Chaudry A; Driver J; Bi WL; Lederer J; Shah K
    Nat Commun; 2020 Aug; 11(1):3912. PubMed ID: 32764562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
    Inocencio JF; Mitrasinovic S; Asad M; Parney IF; Zang X; Himes BT
    Front Immunol; 2024; 15():1424396. PubMed ID: 39346924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Microenvironment in Glioblastoma Subtypes.
    Chen Z; Hambardzumyan D
    Front Immunol; 2018; 9():1004. PubMed ID: 29867979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the immune system in glioblastoma.
    Brown NF; Carter TJ; Ottaviani D; Mulholland P
    Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
    Wang AF; Hsueh B; Choi BD; Gerstner ER; Dunn GP
    Curr Treat Options Oncol; 2024 May; 25(5):628-643. PubMed ID: 38649630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
    Liu Y; Song C; Shen F; Zhang J; Song SW
    PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice.
    Liu L; van Schaik TA; Chen KS; Rossignoli F; Borges P; Vrbanac V; Wakimoto H; Shah K
    Front Immunol; 2023; 14():1324618. PubMed ID: 38274817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
    Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
    Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.